Biocept
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The last earnings update was 129 days ago. More info.
Add to Portfolio Compare Print
- Biocept has significant price volatility in the past 3 months.
BIOC Share Price and Events
7 Day Returns
1 Year Returns
BIOC Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Biocept (BIOC) | -11.1% | 4% | 30% | -89.9% | -99.1% | -99.8% |
| US Biotechs | 0.1% | 1.4% | 20.3% | -0.8% | 20% | 17.9% |
| US Market | 0.4% | 1.6% | 16.4% | 3.5% | 39.4% | 44% |
1 Year Return vs Industry and Market
- BIOC underperformed the Biotechs industry which returned -0.8% over the past year.
- BIOC underperformed the Market in United States of America which returned 3.5% over the past year.
BIOC Value
Is Biocept undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Biocept. This is due to cash flow or dividend data being unavailable. The share price is $1.04.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Biocept's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Biocept's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in USD | $-12.40 |
| NasdaqCM:BIOC Share Price ** | NasdaqCM (2019-03-22) in USD | $1.04 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 36 Publicly-Listed Biotechs Companies | 19.69x |
| United States of America Market PE Ratio | Median Figure of 3,058 Publicly-Listed Companies | 17.52x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Biocept.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:BIOC Share Price ÷ EPS (both in USD) = 1.04 ÷ -12.40 |
-0.08x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Biocept is loss making, we can't compare its value to the US Biotechs industry average.
- Biocept is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Biocept's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -0.08x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
Not available |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 1.62x |
| United States of America Market PEG Ratio | Median Figure of 2,103 Publicly-Listed Companies | 1.48x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Biocept, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Biocept's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in USD | $2.27 |
| NasdaqCM:BIOC Share Price * | NasdaqCM (2019-03-22) in USD | $1.04 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 406 Publicly-Listed Biotechs Companies | 3.35x |
| United States of America Market PB Ratio | Median Figure of 5,157 Publicly-Listed Companies | 1.88x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:BIOC Share Price ÷ Book Value per Share (both in USD) = 1.04 ÷ 2.27 |
0.46x |
* Primary Listing of Biocept.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Biocept is good value based on assets compared to the US Biotechs industry average.
Value checks
We assess Biocept's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Biocept has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
BIOC Future Performance
How is Biocept expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Biocept's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Biocept's earnings growth to the United States of America market average as no estimate data is available.
- Biocept's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqCM:BIOC Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts | 36.2% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 18.4% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 14.6% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 14.3% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2019-12-31 | 5 | 1 | ||
| 2018-12-31 | 3 | -21 | -24 | 2 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 3 | -23 | -25 |
| 2018-06-30 | 4 | -22 | -24 |
| 2018-03-31 | 4 | -21 | -24 |
| 2017-12-31 | 5 | -20 | -22 |
| 2017-09-30 | 5 | -18 | -20 |
| 2017-06-30 | 5 | -16 | -19 |
| 2017-03-31 | 5 | -15 | -18 |
| 2016-12-31 | 3 | -16 | -18 |
| 2016-09-30 | 2 | -16 | -19 |
| 2016-06-30 | 1 | -16 | -19 |
| 2016-03-31 | 1 | -16 | -18 |
| 2015-12-31 | 1 | -15 | -17 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from Biocept Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2019-12-31 | ||||
| 2018-12-31 | -8.49 | -8.49 | -8.49 | 1.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-09-30 | -12.40 |
| 2018-06-30 | -15.44 |
| 2018-03-31 | -19.47 |
| 2017-12-31 | -23.80 |
| 2017-09-30 | -25.95 |
| 2017-06-30 | -31.62 |
| 2017-03-31 | -40.88 |
| 2016-12-31 | -57.63 |
| 2016-09-30 | -78.01 |
| 2016-06-30 | -83.05 |
| 2016-03-31 | -85.96 |
| 2015-12-31 | -92.23 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Biocept will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Biocept's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Biocept has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
BIOC Past Performance
How has Biocept performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Biocept does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Biocept's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Biocept's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Biocept Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 3.39 | -24.86 | 13.21 | 4.09 |
| 2018-06-30 | 3.74 | -24.00 | 13.52 | 3.86 |
| 2018-03-31 | 4.19 | -23.54 | 13.92 | 3.68 |
| 2017-12-31 | 5.07 | -21.61 | 13.53 | 3.36 |
| 2017-09-30 | 5.37 | -20.13 | 13.06 | 3.12 |
| 2017-06-30 | 5.30 | -19.06 | 12.74 | 2.87 |
| 2017-03-31 | 4.68 | -17.96 | 12.01 | 2.74 |
| 2016-12-31 | 3.22 | -18.40 | 11.61 | 2.71 |
| 2016-09-30 | 2.15 | -18.83 | 11.47 | 2.83 |
| 2016-06-30 | 1.27 | -18.58 | 10.96 | 2.91 |
| 2016-03-31 | 0.68 | -18.02 | 10.36 | 2.93 |
| 2015-12-31 | 0.61 | -16.95 | 9.57 | 2.86 |
| 2015-09-30 | 0.47 | -16.21 | 9.02 | 3.14 |
| 2015-06-30 | 0.31 | -15.58 | 8.21 | 3.78 |
| 2015-03-31 | 0.26 | -14.54 | 7.45 | 4.14 |
| 2014-12-31 | 0.13 | -15.87 | 7.34 | 4.50 |
| 2014-09-30 | 0.08 | -14.46 | 6.01 | 4.14 |
| 2014-06-30 | 0.10 | -13.46 | 4.95 | 3.80 |
| 2014-03-31 | 0.13 | -12.44 | 4.00 | 3.39 |
| 2013-12-31 | 0.13 | -9.23 | 2.66 | 3.09 |
| 2013-09-30 | 0.14 | -9.71 | 2.50 | 3.63 |
| 2013-06-30 | 0.13 | -9.72 | 2.34 | 4.17 |
| 2013-03-31 | 0.11 | -10.96 | 2.61 | 5.37 |
| 2012-12-31 | 0.11 | -12.26 | 2.85 | 6.56 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Biocept has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Biocept has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Biocept improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Biocept's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Biocept has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
BIOC Health
How is Biocept's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Biocept's finances.
The net worth of a company is the difference between its assets and liabilities.
- Biocept is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Biocept's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 6.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Biocept Company Filings, last reported 5 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | 8.94 | 1.71 | 8.96 |
| 2018-06-30 | 2.53 | 2.06 | 2.57 |
| 2018-03-31 | 8.51 | 2.35 | 9.27 |
| 2017-12-31 | 1.30 | 2.79 | 2.15 |
| 2017-09-30 | 4.03 | 3.02 | 5.88 |
| 2017-06-30 | 7.34 | 3.51 | 10.00 |
| 2017-03-31 | 10.42 | 3.79 | 14.04 |
| 2016-12-31 | 0.66 | 4.17 | 4.61 |
| 2016-09-30 | -4.56 | 4.37 | 0.68 |
| 2016-06-30 | -0.42 | 4.33 | 3.75 |
| 2016-03-31 | -0.49 | 4.61 | 4.57 |
| 2015-12-31 | 3.69 | 4.67 | 8.82 |
| 2015-09-30 | 6.93 | 4.95 | 12.54 |
| 2015-06-30 | 11.05 | 5.16 | 16.52 |
| 2015-03-31 | 13.58 | 4.89 | 19.29 |
| 2014-12-31 | -0.22 | 4.89 | 5.36 |
| 2014-09-30 | 3.34 | 4.87 | 8.82 |
| 2014-06-30 | 6.88 | 4.71 | 12.46 |
| 2014-03-31 | 9.36 | 0.02 | 10.42 |
| 2013-12-31 | -12.46 | 7.40 | 0.07 |
| 2013-09-30 | -3.51 | 1.55 | 0.30 |
| 2013-06-30 | -8.22 | 3.91 | 0.00 |
| 2013-03-31 | -27.38 | 22.63 | 0.19 |
| 2012-12-31 | -27.38 | 22.63 | 0.19 |
- Biocept's level of debt (19.1%) compared to net worth is satisfactory (less than 40%).
- Biocept had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Biocept has less than a year of cash runway based on current free cash flow.
- Biocept has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.8% each year.
Financial health checks
We assess Biocept's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Biocept has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
BIOC Dividends
What is Biocept's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Biocept
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Biocept's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Biocept's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 21 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2006 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2019-12-31 | ||
| 2018-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Biocept has not reported any payouts.
- Unable to verify if Biocept's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Biocept's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Biocept afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Biocept has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
BIOC Management
CEO
| COMPENSATION | $439,720 |
| AGE | 55 |
| TENURE AS CEO | 5.6 years |
CEO Bio
Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, marketing, operations and reimbursement. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 to August 2013, with his last position being General Manager, North American Sales and Marketing. He served as Account Executive at Impath. Prior to joining Biocept, He served as General Manager for Clarient, a GE Healthcare Company, responsible for all commercial operations including Sales, Marketing, Client Services and Reimbursement. He joined Clarient in 2002 when it was a small publicly traded company and served in several leadership roles including Director, Vice President of Sales, Vice President of Sales and Reimbursement and finally GM. During the time, he was with Clarient, company grew to over $110 million in revenue and was acquired by GE Healthcare. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. Prior to joining Clarient, He was with Impath, an innovative cancer diagnostic company. He has been a Director at Biocept, Inc. since 2013. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (also known as the University of Central Missouri).
CEO Compensation
- Mike's compensation has been consistent with company performance over the past year.
- Mike's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Biocept management team in years:
- The tenure for the Biocept management team is about average.
Management Team
Mike Nall
CEO, President & Director
$440K
55
5.6 yrs
Tim Kennedy
CFO, Senior VP of Operations & Corporate Secretary
$359K
60
2.7 yrs
Lyle Arnold
Senior VP of R&D
$287K
71
7.8 yrs
Soon Kap Hahn
22.2 yrs
Pavel Tsinberg
Director of Technology Development
1.5 yrs
Michael Brown
General Counsel and Compliance & Privacy Officer
1.4 yrs
David Moskowitz
Vice President of Strategy & Corporate Communications
2.4 yrs
Mike Terry
Senior Vice President of Corporate Development
63
Cory Dunn
Vice President of Marketing
0.3 yrs
Veena Singh
Senior Medical Director
$442K
43
4.3 yrs
Board of Directors Tenure
Average tenure and age of the Biocept board of directors in years:
- The tenure for the Biocept board of directors is about average.
Board of Directors
David Hale
Non-Executive Chairman of the Board
$102K
69
8 yrs
Mike Nall
CEO, President & Director
$440K
55
6.2 yrs
Claire Reiss
Chairwoman Emeritus
7.9 yrs
Lyle Arnold
Senior VP of R&D
$287K
71
M. Wilson
Lead Independent Director
$56K
80
Ivor Royston
Independent Director
$41K
72
9.2 yrs
Marsha Chandler
Independent Director
$40K
73
5.3 yrs
Bruce Huebner
Director
$48K
67
5.3 yrs
Bruce Gerhardt
Independent Director
$39K
67
8.4 yrs
Fred Hirsch
Member of Clinical Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12. Oct 18 | Sell | Ally Bridge Group | Company | 05. Oct 18 | 08. Oct 18 | -56,033 | $2.58 | $-138,943 | ||
Management checks
We assess Biocept's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Biocept has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
BIOC News
Simply Wall St News
What Kind Of Investor Owns Most Of Biocept, Inc. (NASDAQ:BIOC)?
Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Companies that have been privatized tend to have low insider ownership. … Biocept is a smaller company with a market capitalization of US$13m, so it may still be flying under the radar of many institutional investors.
Simply Wall St - – Full articleIs Biocept Inc (NASDAQ:BIOC) A Volatile Stock?
If you're interested in Biocept Inc (NASDAQ:BIOC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).
Simply Wall St - – Full articleIs Biocept Inc's (NASDAQ:BIOC) CEO Incentives Align With Yours?
How Does Mike Nall's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m. … It would therefore appear that Biocept Inc pays Mike Nall more than the median CEO remuneration at companies of a similar size, in the same market
Simply Wall St - – Full articleWhy Biocept Inc's (NASDAQ:BIOC) Ownership Structure Is Important
In this analysis, my focus will be on developing a perspective on Biocept Inc’s (NASDAQ:BIOC) latest ownership structure, a less discussed, but important factor. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders. … See our latest analysis for Biocept
Simply Wall St - – Full articleBiocept Inc (NASDAQ:BIOC): Should The Recent Earnings Drop Worry You?
Check out our latest analysis for Biocept Despite a decline, did BIOC underperform the long-term trend and the industry? … To account for any quarterly or half-yearly updates, I use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … I suggest you continue to research Biocept to get a more holistic view of the stock by looking at: Future Outlook: What are well-informed industry analysts predicting for BIOC’s future growth?
Simply Wall St - – Full articleIs It The Right Time To Buy Biocept Inc (BIOC)?
And if you believe that BIOC should be trading at this level in the long run, there’s only an insignificant downside when the price falls to its real value. … Currently, BIOC appears to be trading around its fair value, but given the uncertainty from negative returns in the future, this could be the right time to reduce the risk in your portfolio. … If you’ve been keeping an eye on BIOC for a while, now may not be the most advantageous time to buy, given it is trading around its fair value.
Simply Wall St - – Full articleBIOC Company Info
Description
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company’s cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Details
| Name: | Biocept, Inc. |
| BIOC | |
| Exchange: | NasdaqCM |
| Founded: | 1997 |
| $19,565,729 | |
| 18,813,201 | |
| Website: | http://www.biocept.com |
| Address: |
Biocept, Inc. 5810 Nancy Ridge Drive, San Diego, California, 92121, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | BIOC | Common Stock | Nasdaq Capital Market | US | USD | 05. Feb 2014 | |
| DB | B002 | Common Stock | Deutsche Boerse AG | DE | EUR | 05. Feb 2014 | |
| BST | B001 | Common Stock | Boerse-Stuttgart | DE | EUR | 05. Feb 2014 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/03/23 00:27 |
| End of day share price update: | 2019/03/22 00:00 |
| Last estimates confirmation: | 2018/10/03 |
| Last earnings filing: | 2018/11/14 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
